Abstract: The present invention relates to inactivated microorganisms, preferably inactivated by gamma irradiation, wherein said inactivated microorganisms are viable but not culturable. Furthermore, the present invention relates to said inactivated microorganisms for use in a method of treating intestinal dysbiosis, inflammatory or functional gastrointestinal diseases, autoimmune diseases and diseases caused by pathogenic microorganisms.

Abstract: Use of a composition comprising bacteria to increase the intestinal production of butyric acid, folic acid or niacin and/or to decrease the intestinal production of succinic acid. Moreover, the present invention relates to the use of said composition for the treatment and/or prevention of an intestinal butyrate- and/or succinate-dependent pathological condition. In particular, for the treatment and/or the prevention of intestinal inflammation, diarrhoea, ulcerative colitis or intestinal colopathies.

Abstract: The present invention relates to the use of probiotics to control the inflammatory process of the colon in subjects with structural modifications of the colon wall, preferably in subjects with diverticulosis, and affected by diverticular disease.

Abstract: The present invention relates to the use of a composition comprising bacteria to increase the intestinal production of butyric acid, folic acid or niacin and/or to decrease the intestinal production of succinic acid. Moreover, the present invention relates to the use of said composition for the treatment and/or prevention of an intestinal butyrate- and/or succinate-dependent pathological condition. In particular, for the treatment and/or the prevention of intestinal inflammation, diarrhoea, ulcerative colitis or intestinal colopathies.

Abstract: The present invention relates to mixtures or compositions comprising a chondroitin sulfate of plant origin or an analogue thereof (algae extract) and to the use thereof in the preventive or curative treatment of diseases and symptoms caused by gastric reflux in the gastroesophageal tract or in extra-oesophageal regions, and ulcers, lacerations and/or inflammations of the mucous membranes or the lining tissues of the various anatomical regions present in the tract from the stomach to the oral cavity, also including the upper respiratory tract.

Abstract: The present invention relates to mixtures or compositions comprising a chondroitin sulfate of plant origin or an analogue thereof (algae extract) and to the use thereof in the preventive or curative treatment of diseases and symptoms caused by gastric reflux in the gastroesophageal tract or in extra-oesophageal regions, and ulcers, lacerations and/or inflammations of the mucous membranes or the lining tissues of the various anatomical regions present in the tract from the stomach to the oral cavity, also including the upper respiratory tract.

Abstract: The present invention relates to a composition comprising lactoferrin and, optionally, probiotic bacterial strains and/or N-acetylcysteine and/or hyaluronic acid for oral use as an antiviral agent, preferably for use in the treatment of viral infections of the a respiratory system from a SARS-coronavirus (e.g. COVID-19).

Abstract: The present invention relates to the use of a composition based on bacteria and/or yeasts and/or other microorganisms, taken singularly or in combination, for the treatment of abdominal pain by administering to a patient suffering from Irritable Bowel Syndrome (IBS). In particular, the bacteria comprise Lactobacillus paracasei DG strain deposited with the deposit number CNCMI 1572.

Abstract: Compositions, food products, methods and systems for use in increasing the blood bioavailability of amino acids derived from proteins, preferably proteins of plant origin, comprising a mixture M comprising or, alternatively, consisting of at least one bacterial strain, preferably Lactobacillus paracasei DG® CNCM I-1572 and/or Lactobacillus paracasei LPC-S01™ DSM 26760, and possibly. The compositions food products, methods and systems o the disclosure, can further comprise at least one protein, preferably proteins of plant origin, or a peptide or an amino acid, and in particular includes a food product comprising proteins, preferably of plant origin, and said mixture M of at least one bacterial strain.

Abstract: The present invention relates to a composition which comprises a mixture which comprises or, alternatively, consists of an extract (a) of a fruit of at least one plant of the genus Vaccinium and at least one ingredient (b) acceptable for pharmaceutical or food use and the use thereof in the prevention and/or treatment of diverticular disease or of a pathology deriving therefrom or correlated thereto.

Abstract: The present invention relates to a liquid composition for use in the treatment of gastroesophageal reflux. The composition of the present invention comprises a mixture which comprises or, alternatively, consists of a combination of Aloe vera gel, hyaluronic acid and honey and, optionally, food or pharmaceutical grade additives and/or technological excipients. The composition of the present invention also relates to a medical device comprising a mixture which comprises or, alternatively, consists of a combination of Aloe vera gel, hyaluronic acid and honey and, optionally, food or pharmaceutical grade additives and/or technological excipients. Said composition or composition for a medical device being for use in the preventive and/or curative treatment of the symptoms associated with gastroesophageal reflux and the disease caused thereby, as well as for use in the preventive and/or curative treatment of gastroesophageal reflux disorders.

Abstract: The present invention relates to bacterial strains for use in the treatment of vitamin D deficiency and/or insufficiency and/or diseases, symptoms and/or disorders associated thereto. Furthermore, the present invention relates to compositions comprising at least one of said bacterial strains and at least one vitamin D, preferably vitamin D3, and to the use thereof in the treatment of said vitamin D deficiency and/or insufficiency and/or diseases, symptoms or disorders associated thereto.

Abstract: The present invention relates to bacterial strains and compositions thereof for use in the treatment of viral infections of the respiratory tract, preferably from coronavirus, such as for example a severe acute respiratory syndrome coronavirus (COVID-19), by stimulating and/or modulating cytokines and/or markers involved in the inflammatory processes of said viral infections of the respiratory tract.

Abstract: The present invention relates to a composition comprising probiotics, preferably based on bacteria, in particular of the genus Lactobacillus, to be used for the purpose of preventing and/or treating the disorders affecting the skin, in particular inflammatory disorders, in particular autoinflammatory disorders of dermatological interest such as atopic dermatitis. Furthermore, the composition of the invention is useful for preventing and/or reducing the damage induced by UV radiation, in particular skin aging.

Abstract: The present invention relates to a composition comprising lactoferrin for oral use as an antiviral, preferably for use in the treatment of viral infections of the respiratory system and of symptoms or disorders deriving from, or relating to, said viral infections, preferably SARS-coronavirus viral infections (e.g. COVID-19).

Abstract: The present invention refers to exopolysaccharide molecules, conditioned media or compositions comprising said molecules or media. Moreover, the present invention refers to use of said exopolysaccharide molecules, conditioned media or compositions as prebiotic, preferably to boost immune system.

Abstract: The present invention relates to a topical composition containing a probiotic and hyaluronic acid or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of inflammatory bowel disease.

Abstract: Compositions are described and related methods and food products for increasing the blood bioavailability of amino acids derived from proteins, preferably proteins of plant origin, based on a mixture M including at least one bacterial strain, preferably Lactobacillus paracasei DG® CNCM I-1572 and/or Lactobacillus paracasei LPC-S01™ DSM 26760. Furthermore, the mixture M is described, as well as the compositions and related methods and food products based on mixture M and further comprises at least one protein, preferably proteins of plant origin, or a peptide or an amino acid.

Abstract: The present invention relates to a composition comprising probiotics, preferably based on bacteria, in particular of the genus Lactobacillus, to be used for the purpose of preventing and/or treating the disorders affecting the skin, in particular inflammatory disorders, in particular autoinflammatory disorders of dermatological interest such as atopic dermatitis. Furthermore, the composition of the invention is useful for preventing and/or reducing the damage induced by UV radiation, in particular skin aging.

Abstract: A composition comprising a mixture comprising or, alternatively, consisting of: at least one bacterial strain selected from a group comprising or, alternatively, consisting of bacterial strains belonging to the species Lactobacillus paracasei, Lactobacillus rhamnosus, Bifidobacterium bifidum and Bifidobacterium animalis subsp. Lactis, and preferably, at least one extract of at least one species of berries comprising a polyphenol fraction of said berries and a related method wherein said composition is used as an immunomodulatory and anti-inflammatory agent are disclosed.